Novartis pads Cosentyx's psoriatic arthritis lead with joint-damage label update
admin 21st June 2018 Uncategorised 0As the psoriatic arthritis field heats up, Novartis has added some new data to its Cosentyx label it hopes can stretch out the drug’s lead. This week, the FDA gave the Swiss drugmaker the green light to include results showing Cosentyx could slow the progression of joint structural damage associated with the disease.
More: Novartis pads Cosentyx's psoriatic arthritis lead with joint-damage label update
Source: fierce